Restoring the interplay between the endoplasmic reticulum and mitochondria by gene therapy improves Charcot–Marie–Tooth type 2A disease
Proceedings of the National Academy of Sciences · 2026
DOI: 10.1073/pnas.2530774123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Marine Tessier und 13 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille Univ, INSERM, Marseille Medical Genetics, U1251, Marseille 13005, France. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease, Endoplasmic Reticulum, Mitochondria, GTP Phosphohydrolases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: French National Research agency, Research region sud infrastructure grant, Foundation Teofilo Rossi di Montelera e di Premuda advised by CARIGEST.
Abstract (Originalsprache)
Charcot–Marie–Tooth disease type 2A (CMT2A) is the most common axonal CMT and is associated with an early onset and severe motor neuropathy. CMT2A is mainly caused by dominant mutations in the MFN2 gene, encoding mitofusin-2, a GTPase located in the outer membrane of the mitochondria and endoplasmic reticulum (ER). Mutations in MFN2 affect mitochondrial dynamics. We previously demonstrated that mutated MFN2 further disrupts contacts between the ER and the mitochondria, leading to axonal degeneration. There are no treatments for CMT2A, and those currently under development primarily focus on restoring mitochondrial function. Here, we provide proof of concept that neuronal overexpression of wild-type MFN2 (MFN2 WT ) provides therapeutic benefit in transgenic CMT2A mice as well as in CMT2A-motor neurons derived from induced pluripotent stem cells. Intrathecal delivery of an AAV9 vector expressing MFN2 WT effectively targets motor and sensory neurons, restoring ER–mitochondria contacts and mitochondrial morphology, thereby preserving both neuromuscular junction integrity and motor function. Strikingly, therapeutic efficacy is also achieved by administering the vector after the onset of symptoms. Importantly, AAV administration was well tolerated, with no evidence of hepatotoxicity or dorsal root ganglion inflammation. We further show that CMT2A pathology can be corrected in vitro and in vivo using an ER-targeting MFN1 isoform that selectively enhances ER–mitochondria contacts. These results establish that restoring contacts between the ER and mitochondria using gene therapy is a promising therapeutic avenue for CMT2A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aix Marseille Univ, INSERM, Marseille Medical Genetics, U1251, Marseille 13005, France.
- Département de Génétique Médicale, Hôpital Timone, Assistance Publique- Hôpitaux de Marseille, Marseille 13005, France.
- Centre de Ressources Biologiques, Assistance Publique- Hôpitaux de Marseille, Hôpital Timone Adulte, Biogénopôle, Marseille 13005, France.
- Centre de Référence des Maladies Neuromusculaires et de la Sclérose Latérale Amyotrophique, Assistance Publique- Hôpitaux de Marseille, Centre Hospitalier Universitaire Timone, Marseille, France.
- CNRS, Marseille 13009, France.
- Bertarelli Platform for Gene Therapy, Ecole Polytechnique Fédérale de Lausanne, Geneva 1202, Switzerland.
ORCID-Profile: Nathalie Bonello-Palot, Marc Bartoli, Valérie Delague, Bernard L Schneider, Nathalie Bernard-Marissal
Förderung
- French National Research agency
- Research region sud infrastructure grant
- Foundation Teofilo Rossi di Montelera e di Premuda advised by CARIGEST
- Germaine de Staël
- Starting grant INSERM
Zitieren
APA
Tessier, M., Hamze, Z., Bonello-Palot, N., Roeckel-Trévisiol, N., Da Silva, N., Verlet, I., Broucqsault, N., Bertaux, K., Delmont, E., Attarian, S., Bartoli, M., Delague, V., Schneider, B. L., & Bernard-Marissal, N. (2026). Restoring the interplay between the endoplasmic reticulum and mitochondria by gene therapy improves Charcot–Marie–Tooth type 2A disease. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2530774123
Vancouver
Tessier M, Hamze Z, Bonello-Palot N, Roeckel-Trévisiol N, Da Silva N, Verlet I, et al. Restoring the interplay between the endoplasmic reticulum and mitochondria by gene therapy improves Charcot–Marie–Tooth type 2A disease. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2530774123
BibTeX
@article{Tessier2026,
author = {Tessier, Marine and Hamze, Zeinab and Bonello-Palot, Nathalie and Roeckel-Trévisiol, Nathalie and Da Silva, Nathalie and Verlet, Ilian and Broucqsault, Natacha and Bertaux, Karine and Delmont, Emilien and Attarian, Shahram and Bartoli, Marc and Delague, Valérie and Schneider, Bernard L and Bernard-Marissal, Nathalie},
title = {Restoring the interplay between the endoplasmic reticulum and mitochondria by gene therapy improves Charcot–Marie–Tooth type 2A disease},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
doi = {10.1073/pnas.2530774123}
}
EUVIMED